Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 07 - 13

Efung News | Jingze Bio's JZB32 Project Included in National Science and Technology Major Project –

Recently, Jingze Bio's core pipeline project JZB32 (Recombinant Human Truncated Plasminogen Injection) was officially included in the National Science and Technology Major Project for Innovative Drug R&D, under the initiative "Innovative Drug R&D for Major Fundus Diseases Based on Cell Growth Factors."On July 5, 2026, the project kick-off meeting was grandly held at Wenzhou Medical University, bringing together top experts in ophthalmology and pharmaceutical sciences from across China to conduct in-depth discussions on collaborative R&D of original biologics for fundu...

浏览次数：4

查看详情>>

发布时间: 2026 - 07 - 10

Efung News | 2025 State Science and Technology Awards Announced! Investee Enterprises of Efung Capit

On July 8, 2026, the 2025 State Science and Technology Awards Conference was grandly held at the Great Hall of the People in Beijing. Xi Jinping, General Secretary of the Communist Party of China Central Committee, President of the People’s Republic of China, and Chairman of the Central Military Commission, attended the conference, presented awards to laureates of the State Preeminent Science and Technology Award and other winners, and delivered an important speech.General Secretary Xi emphasized that the period covered by the 15th Five-Year Plan marks a critical stage for advancing the buildi...

浏览次数：7

查看详情>>

发布时间: 2026 - 07 - 09

Efung Hardcore Sharing | The Era of Functional Payloads: ADC Is Shifting from "Killing Cells" to "El

Antibody-Drug Conjugates (ADCs) are assembled through chemical conjugation of three components: antibody, linker, and payload.Over the past two decades, systematic progress has been achieved in antibody target selection, linker stability and release mechanisms, and homogeneity control of the drug-to-antibody ratio (DAR). Third-generation ADCs have already rewritten treatment standards across multiple solid tumor types.However, when it comes to the payload—the core component that determines ADC efficacy and safety—its mechanism of action has long been confined to the single paradigm of "cy...

浏览次数：8

查看详情>>

发布时间: 2026 - 07 - 08

Efung News | HighLight Pharma’s Genoxitenib (TLL-018) Receives CDE Breakthrough Therapy Designation

HighLight Pharma today announced that its independently developed oral, highly selective JAK1/TYK2 dual inhibitor, Genoxitenib (TLL-018), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis (RA).This designation is based on positive topline data from the Phase III registrational study (TARA) of Genoxitenib. The CDE, following its review, determined that Genoxitenib meets the eligibility criteria for Breakthrough Therapy Designation, as it is intended to p...

浏览次数：4

查看详情>>